Bremelanotide / Bremelanotida

Identity and synonyms

Identity follows the supplied name and synonyms; no additional identity description is supplied.

Synonyms: PT-141 · Vyleesi

Peptide or peptide-related · Peptide or peptide derivative

Detailed molecular class: Melanocortin agonist peptide

Supplied sequence or chemical reference

See identity note; no supplier sequence accepted as verification.

Mechanism

Melanocortin receptor agonism.

Evidence and critical reading

Reported scientific and empirical uses

Sexual function

Vyleesi labeling concerns acquired generalized HSDD in premenopausal women; promotion in men or for sexual performance has a different evidence and authorization status.

Human evidence

Clinical evidence and US indication concern acquired generalized HSDD in premenopausal women meeting label criteria.

Preclinical evidence

Sexual-response effects do not establish performance enhancement in men.

Critical reading and limitations

The guide keeps label dosing and handbook quantities separate. Redosing suggested in a handbook is not adopted as an alternative to label restrictions. Approval belongs to the product and indication rather than every PT-141 vial.

Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.

Source-specific regimens

Descriptive source observations, not individual recommendations.

Regulatory product labeling

NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.

Reported by Vyleesi prescribing information

1.75 mg · Amount per administration

Frequency: As needed; no more than one dose in 24 h; over eight monthly not recommended by label.
Duration: Not stated on selected page.
Route: Subcutaneous
Context: Acquired/generalized HSDD in premenopausal women per US label.
Presentation: Autoinjector: 1.75 mg/0.3 mL.
Interpretation: Do not transfer this to men or sexual performance as approved indications.

R31 · October 16, 2026

Human-study exposure

Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.

Empirical handbook

Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.

Regulation and safety

Jurisdiction-specific regulatory context

US: Vyleesi approved for narrow HSDD indication, not male performance.

Adverse effects and unknowns

Nausea, transient BP increase and pigmentation. Contraindicated with uncontrolled hypertension or known cardiovascular disease. Delayed gastric emptying can affect oral drugs; oral naltrexone exposure can fall.

Contraindications

See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.

A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.

Interactions

Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.

Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.

Studies and trials

Selected studies

No selected studies are attributed in this record.

Trials attributed in the package

No trials are attributed in this record.

Trial registration does not establish efficacy or validate commercial material.

Query candidates; attribution pending

bremelanotide · 10 unfiltered query results, not authenticated trials

Query verification: October 16, 2026

Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.

View trial registry query

NCT06867835 · Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast MilkRegistry status: CompletedLast update posted: January 13, 2026Query verification: October 16, 2026

NCT06565611 · A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityRegistry status: Active, not recruitingLast update posted: March 6, 2025Query verification: October 16, 2026

NCT04943068 · A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)Registry status: CompletedLast update posted: November 13, 2024Query verification: October 16, 2026

Source issues and references

References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.

R31
Vyleesi prescribing information
pdf01
PEPNEXA 2.pdf
October 16, 2026
pdf02
ELLA PEPTIDES.pdf
October 16, 2026
pdf03
zlz list 26.8.5.pdf
October 16, 2026
pdf05
PEPNEXA.pdf
October 16, 2026
pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
pdf09
PeptideFactory.pdf
October 16, 2026